Wang Yu, Feng Xiaojian, Li Yue, Niu Songlin, Li Jinxin, Shi Honghong, Wang Gaoling, Wang Lihua
Department of Nephrology, Second Hospital, Shanxi Medical University, Taiyuan, China.
Department of Nephrology, Second Hospital, Shanxi Medical University, Taiyuan, China.
Int Immunopharmacol. 2025 May 8;154:114562. doi: 10.1016/j.intimp.2025.114562. Epub 2025 Apr 1.
Renal tubular interstitial inflammation is a central driver of the pathogenesis of diabetic kidney disease (DKD). Peroxisome proliferator-activated receptor alpha (PPARα), predominantly expressed in renal tubular epithelial cells (TECs), plays a key role in regulating inflammation. However, the precise molecular mechanisms through which PPARα exerts its protective effects in DKD remain unclear.
Single-cell RNA sequencing data from the GEO database revealed a marked reduction in PPARα expression in the proximal TECs of early-stage DKD patients. To investigate its potential role, we utilized an AAV9-PPARα viral vector to induce PPARα overexpression in TECs within a DKD mouse model. RNA sequencing of kidney tissues from both DKD and PPARα-overexpressing DKD mice was performed to identify key differentially expressed genes and signaling pathways. These findings were subsequently validated by in vitro and in vivo experiments.
PPARα overexpression significantly improved renal function, reduced interstitial fibrosis, attenuated inflammatory cytokine expression, and markedly decreased M1 macrophage infiltration. Notably, PPARα inhibited RIP1/RIP3/MLKL-mediated necroptosis in TECs, resulting in a substantial delay in DKD progression. Furthermore, NF-κB signaling played a crucial role in PPARα-mediated regulation of inflammation and necroptosis in TECs.
In summary, PPARα plays a pivotal role in modulating inflammation and necroptosis in DKD. Targeting PPARα in TECs represents a promising therapeutic strategy for slowing the progression of DKD and potentially reversing early renal damage. These findings open up new avenues for PPARα-targeted therapies in DKD and other chronic kidney diseases.
肾小管间质炎症是糖尿病肾病(DKD)发病机制的核心驱动因素。过氧化物酶体增殖物激活受体α(PPARα)主要在肾小管上皮细胞(TECs)中表达,在调节炎症中起关键作用。然而,PPARα在DKD中发挥保护作用的确切分子机制仍不清楚。
来自GEO数据库的单细胞RNA测序数据显示,早期DKD患者近端TECs中PPARα表达显著降低。为了研究其潜在作用,我们利用AAV9-PPARα病毒载体在DKD小鼠模型的TECs中诱导PPARα过表达。对DKD小鼠和PPARα过表达的DKD小鼠的肾组织进行RNA测序,以鉴定关键的差异表达基因和信号通路。这些发现随后通过体外和体内实验得到验证。
PPARα过表达显著改善肾功能,减少间质纤维化,减轻炎性细胞因子表达,并显著减少M1巨噬细胞浸润。值得注意的是,PPARα抑制TECs中RIP1/RIP3/MLKL介导的坏死性凋亡,从而显著延缓DKD进展。此外,NF-κB信号在PPARα介导的TECs炎症和坏死性凋亡调节中起关键作用。
总之,PPARα在调节DKD中的炎症和坏死性凋亡中起关键作用。靶向TECs中的PPARα是减缓DKD进展并可能逆转早期肾损伤的一种有前景的治疗策略。这些发现为DKD和其他慢性肾脏病的PPARα靶向治疗开辟了新途径。